---
title: "Scienture posts revised investor presentation, will present to analysts and investors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298958444.md"
description: "Scienture Holdings, Inc. (SCNX) posted a revised investor presentation on its website on September 14, 2026. The company intends to use this presentation in meetings with analysts, potential investors, and other interested parties. The document serves as summary information and should be reviewed alongside SEC filings and public announcements. It contains forward-looking statements, for which the company disclaims any obligation to update."
datetime: "2026-09-14T20:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298958444.md)
  - [en](https://longbridge.com/en/news/298958444.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298958444.md)
generator: "portal-rs"
---

# Scienture posts revised investor presentation, will present to analysts and investors

**Scienture posted a revised investor presentation and will present it to analysts, investors and other parties.**

**Key Highlights:**

-   Revised investor presentation posted to the company website on September 14, 2026.
-   Presentation will be used in meetings with analysts, potential investors and other interested parties.
-   Presentation is summary information and should be considered alongside the company’s SEC filings and public announcements.
-   Presentation contains forward-looking statements and the company disclaims any obligation to update them.

Original SEC Filing: Scienture Holdings, Inc. \[ SCNX \] - 8-K - Sep. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SCNX.US](https://longbridge.com/en/quote/SCNX.US.md)

## Related News & Research

- [SCNX: Rapid revenue growth and FDA-approved launches highlight a strong specialty pharma pipeline](https://longbridge.com/en/news/298957496.md)
- [Analyst Maintains Buy Rating and $1.50 Price Target on Scienture Amid Strong Early Commercialization for Arbli and Rezenopy](https://longbridge.com/en/news/296005457.md)
- [Microsoft's Biggest AI Customer Is Also Its Biggest Risk](https://longbridge.com/en/news/299731848.md)
- [Micron's (MU) AI Boom Could Outlast the Memory Cycle](https://longbridge.com/en/news/299769666.md)
- [Meta Platforms’ Petal Cable Puts Corning at the Center of AI’s Bandwidth Boom](https://longbridge.com/en/news/299777169.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**